- Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug dosesThe two biggest players in the obesity market are headed to court. Novo Nordisk sued Eli Lilly on Tuesday over what it claims are “maliciously and deceptively false” ads comparing the highest dos…Endpoints · 3d ago↗ source
- ‘We’re moving quickly’: Startup bags rare disease drug as Thiel-backed CEO eyes $50M fundraiseA rare disease startup with a mission to repurpose proven drugs has licensed a Chinese formulation of a well-known medicine and set its sights on a $50 million fundraise.Fierce Biotech · 3d ago↗ source
- Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesityWith PolyPeptide manufacturing peptides such as GLP-1 medicines, Samsung Biologics has identified the deal as a way to tap into fast-growing demand for obesity drug production services.